Ya know, I don't think you're dreaming, assuming the company remains independent that long. But given the Bakers' recent purchases, their track record and Big Pharma's desperate needs for pipelines and science, I'm guessing that SGEN will be absorbed by the Borg within a year or so.
Kool, if I'm reading it right, Abbvie paid a 100 percent premium for Stemcentrx - that is, it doubled that company's market value overnight. So...yeah, I'd agree. That deal sets something of a floor for the inevitable buyout of the much-farther-ahead SGEN, imo.
Here are some highlights of today’s SGEN conference call:
- Though some analysts are calling today’s revenue results a miss, CEO Clay Siegall said that full-year guidance for Adcetris sales in U.S. and Canada remains at $255-275 million. He attributed the alleged miss, if it can be called that, on cyclical inventory and first-quarter seasonal sales issues.
- Asked how big Adcetris might be, he said: “We think the opportunity is vast.”
- He announced that SGEN is establishing a European operations base in Switzerland.
- He and his staff repeatedly expressed considerable excitement about Vadastuximab Talirine (SGN-CD33A). “This is clearly an active drug….,” Siegall said. “Stay tuned for more information.” Asked about seeking FDA breakthrough designation for 33A, he deferred from answering directly, but said: “We’re really encouraged with our data. ”
- He expressed significant confidence in the phase 1 data from ASG-15ME and ASG-22ME to be released at the ASCO annual meeting in June – regarding bladder cancer and other solid tumors.
- Regarding the big jump in R&D expenses, the company called the jump consistent with guidance and said it largely reflected work that was started to get the 33A program into pivotal trials.
I’m was distracted about half-way through the call and I’m sure I missed important elements, especially regarding the pipeline. As always, I urge you to listen to the replay.
You said they would beat. Wall Street says they missed. It doesn't matter other than it shows that you're still an idiot - and back on ignore.
At this stage of the business, imo, earnings reports are mostly insignificant - especially since SGEN consistently hits its sales targets - and they never seem to have an enduring affect on the share price. It's the pipeline and the trials (and the takeover potential) that are most significant, imo.
Adam Feuerstein @adamfeuerstein 19m19 minutes ago
$AGN $PFE breakup should be good for biotech/drug M&A.
CNBC Now @CNBCnow 8m8 minutes ago
BREAKING: Pfizer and Allergan will mutually terminate their merger tomorrow morning - sources (via @davidfaber)
According to the rumor mill, Pfizer is leaning toward abandoning its deal with Allergen, and biotech watchers are predicting that such an action - if it happens - could free up a lot of cash and unleash a bidding war between them (and others) for biotechs.
Right. As others noted, exactly four shares traded at that price and only 45 shares traded at a similarly depressed price. As usual, someone was trying to mess with our heads.
Don't quite understand the question. All of the purchases appear in the Bakers' SEC filings, which is the important thing, and you can find links to them on SGEN's website. (Also, each purchase has been noted on this message board, many with followup discussions.) If you're referring to the Yahoo finance page dedicated to SGEN, only SEC filings made by SGEN itself will show up there. The Bakers are required to make their own SEC filings regarding their purchases of SGEN shares, so those transactions wouldn't show up on a list of SEC documents filed by SGEN.
It appears from the grayed out (ignored) original post that you are responding to the multi-aliased, thinking-challenged, only-shows-up-on-red-days troll known here under the following names: fstout57/rickarooski/quadhole/quadhole1/mauihope/smelky/etc. His elevator never reaches the top floor. Take it from board veterans: It's really better not to feed the troll.
Interesting perspectives. Following the logic thread here, the Bakers obviously are buying hand over fist, with the intention of profiting from their action. They have a history of arranging or supporting biotech sales to Big Pharmas. At this point, as others have noted, the only way they can unwind their huge (and growing) position is through a sale of SGEN. As insiders, they can't be buying if an offer is on the table at the moment. Hence: They intend, perhaps in association with management, to control the terms of what is now the inevitable sale of SGEN. This means it will come 1. At a fair (high) price and 2. Very possibly through a bidding war, especially if a Goldman Sachs co-conspirator makes a lowball public offer and 3. At a time of their choosing, but - given recent actions on their part - very likely sooner than some have believed.
I'm not sure that Echelon has slipped. The details escaped me during his presentation yesterday, but my impression was that Siegall merely tightened the time frame for readout, clipping a few months off the back end. I'd have to listen to it again, though, to be sure about that.
What's amazing to me - and a little unsettling - is that the Bakers have managed to buy all of these shares on the open market without effectively turbocharging the share price. That's to their personal credit and it's a testament to their trading skills, though it's not necessarily to our immediate benefit. Still, one had to believe that sooner or later, probably sooner, the market will wake up to what's happening here and decide that it better follow the Bakers' lead and...boom...get behind this stock big-time (and close out any short positions pronto).
I'm too lazy to add it up, but it looks like they bought more than 1 million more shares yesterday and today. FWIW, during today's investor presentation, CEO Clay Siegall expressed noteworthy confidence in the LIV-1A trial in breast cancer.
Mslans, welcome. SGEN always has been volatile. It gets played a lot by the hedgies, the traders and the shorts. I suggest that you just continually do your research and due diligence to determine if anything real is behind the volatility (it rarely is), and that you keep your eyes on the Bakers, thinking of them as canaries in the coal mine. They know better than any other investors in the world what's happening inside that company and what its prospects might be. If they're still holding or buying, that tells you something; if they start selling, that also will tell you something.
I see eight recent grayed out/ignored posts. I take it that the multi-aliased sanity-challenged math-deficient troll known as fstout57/quadhole/quadholes/rickarooski/term14/mauihope/etc. is off his meds and back again.